Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Dexcom ( (DXCM) ).
On October 24, 2025, Dexcom‘s Board of Directors expanded to include Dr. Euan Ashley, a renowned researcher and clinician, who will serve on the Nominating and Governance Committee and the Technology Committee. This appointment, along with the planned addition of Jacob S. Leach in January 2026, is part of Dexcom’s strategic efforts to strengthen its leadership in medical technology and healthcare innovation, enhancing its capacity to advance metabolic health globally.
The most recent analyst rating on (DXCM) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.
Spark’s Take on DXCM Stock
According to Spark, TipRanks’ AI Analyst, DXCM is a Outperform.
Dexcom’s overall stock score is driven by strong financial performance and positive earnings call insights, highlighting robust revenue growth and strategic expansions. However, technical analysis indicates potential bearish momentum, and the high P/E ratio suggests overvaluation concerns. The absence of a dividend yield further impacts the valuation score.
To see Spark’s full report on DXCM stock, click here.
More about Dexcom
Dexcom, founded in 1999, is a leader in glucose biosensing technology, transforming diabetes management and glucose tracking to help individuals gain better control over their health.
Average Trading Volume: 4,964,615
Technical Sentiment Signal: Strong Sell
Current Market Cap: $27.58B
Find detailed analytics on DXCM stock on TipRanks’ Stock Analysis page.